Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mollee

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
Journal of Geriatric Oncology|February 21, 2025
Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic reviewAaron Sia, Sakshi Chopra, Victoria Y Ling, et al.
Clinical Proteomics|November 1, 2016
Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometryPeter Mollee, Samuel Boros, Dorothy Loo, et al.
Internal Medicine Journal|February 22, 2026
An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapyAnthea Gibbons, Lipi Chakravorty, Hasib Sidiqi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
CD62L as a therapeutic target in chronic lymphocytic leukemiaMelinda Burgess, Devinder Gill, Richa Singhania, et al.
Internal Medicine Journal|February 12, 2020
Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devicesMarc L Ellis, Satomi Okano, Andrew McCann, et al.
Thrombosis and Haemostasis|January 12, 2012
Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian studyMarie-Christine Morel-Kopp, Chee Wee Tan, Timothy A Brighton, et al.
British Journal of Haematology|March 7, 2012
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisPeter Mollee, Campbell Tiley, Ilona Cunningham, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
Hematological Oncology|June 16, 2006
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationColm Keane, Simon Gibbs, John F Seymour, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
Journal of Geriatric Oncology|February 21, 2025
Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic reviewAaron Sia, Sakshi Chopra, Victoria Y Ling, et al.
Clinical Proteomics|November 1, 2016
Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometryPeter Mollee, Samuel Boros, Dorothy Loo, et al.
Internal Medicine Journal|February 22, 2026
An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapyAnthea Gibbons, Lipi Chakravorty, Hasib Sidiqi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
CD62L as a therapeutic target in chronic lymphocytic leukemiaMelinda Burgess, Devinder Gill, Richa Singhania, et al.
Internal Medicine Journal|February 12, 2020
Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devicesMarc L Ellis, Satomi Okano, Andrew McCann, et al.
Thrombosis and Haemostasis|January 12, 2012
Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian studyMarie-Christine Morel-Kopp, Chee Wee Tan, Timothy A Brighton, et al.
British Journal of Haematology|March 7, 2012
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisPeter Mollee, Campbell Tiley, Ilona Cunningham, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
Hematological Oncology|June 16, 2006
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationColm Keane, Simon Gibbs, John F Seymour, et al.
Pageof 15